ELTX Elicio Therapeutics Inc.

Price (delayed)

$4.24

Market cap

$43.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.63

Enterprise value

$37.7M

Highlights
ELTX's debt is down by 3.5% QoQ
The quick ratio has shrunk by 89% YoY but it has soared by 50% QoQ
Elicio Therapeutics's EPS has soared by 88% YoY but it has decreased by 24% from the previous quarter
ELTX's equity has dropped by 88% year-on-year and by 57% since the previous quarter
The net income has declined by 34% year-on-year and by 11% since the previous quarter

Key stats

What are the main financial stats of ELTX
Market
Shares outstanding
10.27M
Market cap
$43.55M
Enterprise value
$37.7M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$38.24M
EBITDA
-$36.83M
Free cash flow
-$36.77M
Per share
EPS
-$8.63
Free cash flow per share
-$3.58
Book value per share
$0.48
Revenue per share
$0
TBVPS
$2.38
Balance sheet
Total assets
$24.48M
Total liabilities
$19.61M
Debt
$6.67M
Equity
$4.87M
Working capital
$8.18M
Liquidity
Debt to equity
1.37
Current ratio
2.37
Quick ratio
2.1
Net debt/EBITDA
0.16
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-129.7%
Return on equity
-293.8%
Return on invested capital
-310.5%
Return on capital employed
-206.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELTX stock price

How has the Elicio Therapeutics stock price performed over time
Intraday
-7.22%
1 week
13.37%
1 month
-48.1%
1 year
-58.95%
YTD
-49.16%
QTD
3.16%

Financial performance

How have Elicio Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.18M
Net income
-$38.99M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 48% year-on-year and by 7% since the previous quarter
The net income has declined by 34% year-on-year and by 11% since the previous quarter

Growth

What is Elicio Therapeutics's growth rate over time

Valuation

What is Elicio Therapeutics stock price valuation
P/E
N/A
P/B
8.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Elicio Therapeutics's EPS has soared by 88% YoY but it has decreased by 24% from the previous quarter
ELTX's equity has dropped by 88% year-on-year and by 57% since the previous quarter
The price to book (P/B) is 33% higher than the last 4 quarters average of 7.2

Efficiency

How efficient is Elicio Therapeutics business performance
The company's return on assets has shrunk by 118% YoY and by 27% QoQ
The ROE has plunged by 83% from the previous quarter and by 20% YoY
ELTX's return on invested capital is down by 8% since the previous quarter but it is up by 6% year-on-year

Dividends

What is ELTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELTX.

Financial health

How did Elicio Therapeutics financials performed over time
The total assets is 25% greater than the total liabilities
The quick ratio has shrunk by 89% YoY but it has soared by 50% QoQ
The current ratio has plunged by 88% YoY but it has grown by 41% from the previous quarter
ELTX's debt is 37% higher than its equity
Elicio Therapeutics's debt to equity has soared by 125% from the previous quarter
ELTX's equity has dropped by 88% year-on-year and by 57% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.